A number of investment brokers have recently updated their price targets on shares of AcelRx Pharmaceuticals, Inc. (ACRX). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/06/2016 – AcelRx Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Seaport Global Securities.

05/03/2016 – AcelRx Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 7 price target on the stock.

10/30/2015 – AcelRx Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Jefferies. They now have a USD 7 price target on the stock.

10/05/2015 – AcelRx Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 10.5 price target on the stock.

08/04/2015 – AcelRx Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Cowen.

05/12/2015 – AcelRx Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 3.5 price target on the stock.

05/06/2015 – AcelRx Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Mizuho. They now have a USD 3 price target on the stock.

05/05/2015 – AcelRx Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 7 price target on the stock.

04/27/2015 – Global Hunter Securities began new coverage on AcelRx Pharmaceuticals, Inc. giving the company a “accumulate” rating. They now have a USD 22 price target on the stock.

03/10/2015 – AcelRx Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Canaccord Genuity. They now have a USD 6 price target on the stock.

03/10/2015 – AcelRx Pharmaceuticals, Inc. had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 8 price target on the stock.

07/29/2014 – AcelRx Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at Piper Jaffray. They now have a USD 8 price target on the stock.

03/04/2014 – EVA Dimensions began new coverage on AcelRx Pharmaceuticals, Inc. giving the company a “hold” rating.

12/17/2013 – AcelRx Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 16.5 price target on the stock.

The share price of AcelRx Pharmaceuticals, Inc. (ACRX) was up +4.19% during the last day of trading, with a day high of 3.27. 285759 shares were traded during the last session.

The stock’s 50 day moving average is 3.41 and its 200 day moving average is 3.85. The stock’s market capitalization is 143.56M. AcelRx Pharmaceuticals, Inc. has a 52-week low of 2.59 and a 52-week high of 5.88.

View other investors thoughts on AcelRx Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.